IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4417
Positioning
Market Dominance
Manufacturing
Medical Equipment
$4M
Francois Michelon
ENDRA Life Sciences Inc. develops thermo-acoustic enhanced ultrasound technology. Technology transmits sound waves, which bounce off tissues, organs, and blood in the body. Thermoablative surgery, vascular imaging, and tissue perfusion technologies also offer diagnostic imaging technologies.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$NDRA ENDRA Life Sciences Inc. | 32 | 21 | 30 | 29 | - | - | -3624.9% | -316.3% | - | - | - | - | 0.0% | 1046.0x | $4M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
ENDRA Life Sciences Inc. (NDRA) receives a "Avoid" rating with a composite score of 31.5/100. It ranks #4417 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Francois Michelon
Chief Executive Officer
Labor Force
20
21
25
19
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for NDRA
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for NDRA.
View All RatingsHigh margin volatility — erratic forensic earnings quality
ROE proxy -3624.9% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 9yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags ENDRA Life Sciences Inc. with an Avoid rating, assigning a composite score of 31.5/100 and 1 out of 5 stars. Ranked #4417 of 7,333 stocks, NDRA falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
ENDRA Life Sciences Inc. registers a weak quality score of just 21/100, indicating significant profitability challenges. The company reports a return on equity of -3624.9% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 30/100, NDRA appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 26.88x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
ENDRA Life Sciences Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -316.3% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
ENDRA Life Sciences Inc. is experiencing notably weak momentum with a score of just 29/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth data is not currently available, while a beta of 2.00 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
ENDRA Life Sciences Inc. registers a low stability score of 19/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 2.00 and a debt-to-equity ratio of 1046.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
NDRA carries a short interest score of 75/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include high market sensitivity (beta: 2.00), elevated leverage (D/E: 1046.00x), micro-cap liquidity risk. At $4M market cap (micro-cap), ENDRA Life Sciences Inc. offers reasonable institutional liquidity.
ENDRA Life Sciences Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4417 of 7,333 overall (40th percentile). Key comparisons include ROE of -3624.9% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While NDRA currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (19) would have the largest impact on the composite score.
ROE 146064% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 522900% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate ENDRA Life Sciences Inc. (NDRA) as Avoid with a composite score of 31.5/100 at a current price of $3.77. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in value (30th percentile) and momentum (29th percentile), which together account for the majority of the composite score. Offsetting weakness in stability (19th percentile) and quality (21th percentile) tempers our overall conviction. We assign a No Moat rating (13/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; balance sheet deleveraging progress. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
ENDRA Life Sciences Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 31.5/100 places it at rank #4417 in our full 7,333-stock universe. At $4M in market capitalization, ENDRA Life Sciences Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (29th percentile) suggest caution regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for ENDRA Life Sciences Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $3.77, ENDRA Life Sciences Inc. is trading at a premium to fundamental value. Our value factor score of 30/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 26.9x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Avoid rating (composite 31.5/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (1046% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Weak momentum (29th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
Below-average quality (21th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a Very High uncertainty rating to ENDRA Life Sciences Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 2.00), significant leverage (1046% debt-to-equity), below-average price stability (19th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 2.00); significant leverage (1046% debt-to-equity); below-average price stability (19th percentile); weak quality scores (21th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 19th percentile and quality factor at the 21th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our very high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate ENDRA Life Sciences Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-3624.9%), elevated leverage (1046% D/E), weak asset returns (ROA -316.3%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — ENDRA Life Sciences Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, ENDRA Life Sciences Inc. receives a Avoid rating with a composite score of 31.5/100 (rank #4417 of 7,333). Our quantitative framework assigns a No Moat (13/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 25/100.
Our analysis does not support a constructive view on ENDRA Life Sciences Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign ENDRA Life Sciences Inc. a meaningful economic moat, scoring 13/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and economic value creation (2.5/20). GM N/A vs sector 43%, OM N/A vs sector 1%. ROE proxy -3624.9% (sector -2.5%). These pillars form the core of ENDRA Life Sciences Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect ENDRA Life Sciences Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 21/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -3624.9% and ROA of -316.3%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -3624.9% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 1046%, which may limit financial flexibility. The sector median D/E is 0%, putting ENDRA Life Sciences Inc. at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
High beta of 2.00 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
Above 50MA
37.18%
Net New Highs
+51081
ANN ARBOR, Mich., December 04, 2025--ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermo-acoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS’ thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%.
ANN ARBOR, Mich., November 20, 2025--ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in biomarker imaging technologies for the early detection and monitoring of metabolic dysfunction-associated liver disease ("MASLD") and metabolic dysfunction-associated steatohepatitis ("MASH"), today announces encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, which is a key b
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Vast Renewables Limited (NASDAQ: VSTE) rose 213.9% to $9.70 in pre-market trading after jumping 39% on Thursday. MediaCo Holding Inc. (NASDAQ: MDIA) gained 84% to $0.9601 in pre-market trading after dipping more than 17% on Thursday. Galera Therapeutics, Inc. (NASDAQ: GRTX) gained 49.5% to $0.2093 in pre-market trading. Galera Therapeutics posted fourth-quarter results on Thursday. Qilian International Holding Group Limited (NASDAQ: QLI) shares gained 32.2% to $0.8399 in pre-market trading. Sunshine Biopharma, Inc. (NASDAQ: SBFM) gained 30.7% to $0.0791 in pre-market trading after the company reported operating results for the fiscal year ended Dec. 31, 2023. Xilio Therapeutics, Inc. (NASDAQ: XLO) shares rose 26.8% to $1.37 in pre-market ...
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion. RayzeBio shares gained 100% to $61.38 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers ARB IOT Group Limited (NASDAQ: ARBB) shares rose 270% to $3.4850 after gaining around 18% on Friday. IMAC Holdings, Inc. (NASDAQ: BACK) shares jumped 108% to $5.05 after jumping 53% on Friday. Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) jumped 75% to $2.0988 after the company announced 95% accuracy results for HYLA blood sensor. Gracell Biotechnologies Inc. (NASDAQ: GRCL) shares gained 60.3% to $9.92 after AstraZeneca announced plans to buy Gracell Biotechnologies for up to $1.2 billion. Science 37 Holdings, Inc. (NASDAQ: SNCE) jumped 52% to $6.62. Science 37 Holdings got notification from Nasdaq indicating the company regained compliance with minimum closing bid price requirement for continued listing. Volcon, Inc. (NASDAQ: VLCN) rose 49.8% to $0.1483 after jumping around 24% on Friday. Sight Sciences, Inc. (NASDAQ: SGHT) gained 48.9% to $5.42. AERWINS Technologies Inc.(NASDAQ: AWIN) gained 36.4% to $0.1637 after the company entered into a letter of intent to form an entity with Helicopter Technology. The company will own 70% and Helicopter Technology will own 30%. SCWorx Corp. (NASDAQ: WORX) rose 32% to $2.3349 after the company announced that it signed a definitive agreement and plan of merger with American Environmental Partners. 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) gained 30% to $1.1750 after the company announced IRB approval of its Phase IIA clinical study ...
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 127.8% to $0.1269. The company recently reported second-quarter results. AERWINS Technologies Inc. (NASDAQ: AWIN) jumped 40% to $0.1801. Know Labs, Inc. (NYSE: KNW) shares jumped 38.8% to $0.6180. Novonix Limited (NASDAQ: NVX) gained 27.4% to $2.37 after the company announced it achieved high-performance battery grade synthetic graphite production milestones with Generation 3 Furnaces at its Tennessee facility. AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares rose 26.3% to $0.1293 after gaining 10% on Thursday. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares jumped 20.8% to $5.61 after the company announced the FDA extended its BLA Priority Review for lifileucel amid resource constraints. Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) gained 19.5% to $5.61. Faraday Future Intelligent Electric reported that one of FF's newest car owners and Developer Co-Creation Officers, Kelvin Sherman, will take delivery of his FF 91 2.0 Futurist Alliance at FF's "919 Developers AI Co-Creation Festival" to be held on Sept. 19. 5E Advanced Materials, Inc. (NASDAQ: FEAM) gained 17.6% to $2.73. Mullen Automotive, Inc. (NASDAQ: MULN) shares surged 17.4% to $0.6699 after surging 15% on Thursday. Shineco, Inc. (NASDAQ: SISI) climbed 15.8% to $0.1448. Canopy Growth Corporation (NASDAQ: CGC) climbed 15% to $1.4390. Cara Therapeutics, Inc. (NASDAQ: CARA) gained 15% to $2.38. Soleno Therapeutics, Inc. (NASDAQ: SLNO) rose 14.5% to ...